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Abstract
Due to the inexorable invasion of our hospitals and communities by drug-resistant bacteria, there is a pressing need for
novel antibacterial agents. Here we report the development of a sensitive and robust but low-tech and inexpensive high-
throughput metabolic screen for novel antibiotics. This screen is based on a colorimetric assay of pH that identifies
inhibitors of bacterial sugar fermentation. After validation of the method, we screened over 39,000 crude extracts derived
from organisms that grow in the diverse ecosystems of Costa Rica and identified 49 with reproducible antibacterial effects.
An extract from an endophytic fungus was further characterized, and this led to the discovery of three novel natural
products. One of these, which we named mirandamycin, has broad-spectrum antibacterial activity against Escherichia coli,
Pseudomonas aeruginosa, Vibrio cholerae, methicillin-resistant Staphylococcus aureus, and Mycobacterium tuberculosis. This
demonstrates the power of simple high throughput screens for rapid identification of new antibacterial agents from
environmental samples.
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Introduction
Microbes that live together in the environment develop long-
lasting methods to keep each other at bay. As a result, many of our
most effective bactericidal agents have come from environmental
organisms. These include glycopeptides such as vancomycin first
isolated in 1953 [1], b-lactam derivatives such as penicillin first
isolated in 1929, and aminoglycosides [2,3].
The emergence of bacteria with resistance to multiple anti-
microbial agents has motivated the development of high thro-
ughput chemical screens (HTS) to identify novel antibiotics. These
screens differ in the number of samples that can reasonably be
evaluated and the level of technology required to carry out the
screen [4–7]. Furthermore, some screening assays assess inhibition
of a known, purified bacterial target, while others measure toxicity
to intact bacteria. The advantage of the former approach is that
the target of inhibition is known for any identified compound. The
great disadvantage, however, is that, in secondary screens, the
compound is often found to have no activity against intact bacteria
due to inadequate penetration, rapid efflux, or inactivation by
bacterial products [8]. For this reason, compounds discovered in
screens using whole cells are often farther along the path to the
development of a successful antibacterial agent.
Here, we describe a sensitive and robust colorimetric whole cell-
based HTS for antibacterial compounds. We used this assay to
screen a collection of over 39,000 crude extracts from organisms
that grow in the diverse ecosystems of Costa Rica. Forty-nine
antibacterial extracts were identified, and, as proof of principle, one
was further fractionated, leading to the elucidation of three novel
natural products. One ofthesewasfoundto haveactivityagainst the
acid-fast bacterium, Mycobacterium tuberculosis, the Gram-positive
bacterium, methicillin-resistant Staphylococcus aureus (MRSA), and
several Gram-negative bacteria. Our results demonstrate the utility
of simple metabolic screens in rapid identification of novel, broad-
spectrum antimicrobial agents.
Methods
Bacterial strains and media
A V. cholerae O139 strain MO10 (PW357) was used for screening
[9]. As a control, we used a V. cholerae phosphoenolpyruvate pho-
sphotransferase (PTS) mutant (DEI, PW961), which is unable to
transport sucrose [10]. Mycobacterium tuberculosis H37Rv (ATCC
27294), Escherichia coli (ATCC 25922), carbapenemase-positive
Klebsiella pneumonia (ATCC BAA-1705), and methicillin-resistant
Staphylococcus aureus (MRSA, ATCC BAA-976) were used for
further evaluation of antibacterial activity.
A previously described minimal medium (MM) supplemented
with sucrose (0.5% wt/vol), thymol blue (0.006% wt/vol) and
bromothymol blue (0.006% wt/vol) (pH-MM
Suc) was used for the
HTS [10]. In secondary screens, MM was also supplemented with
PLoS ONE | www.plosone.org 1 February 2012 | Volume 7 | Issue 2 | e31307glucose (0.5% wt/vol), thymol blue (0.006% wt/vol), and bro-
mothymol blue (0.006% wt/vol) (pH-MM
Glu) or pyruvate (0.5%
wt/vol) (MM
Pyr).
M. tuberculosis H37Rv was grown at 37uC in Middlebrook 7H9
liquid medium (Difco) supplemented with albumin (0.5% wt/vol),
dextrose (10 mM), glycerol (0.2% vol/vol) and Tween 80 (0.05%
vol/vol) (7H9-TW80-ADC).
Fungal culture
Agar plugs containing the endophytic fungal isolate 1223-D
were initially grown at 25uC on yeast malt agar plates sup-
plemented with streptomycin (30 mg/mL) and chlortetracycline
(12 mg/mL). After one week, 3 macerated agar plugs were placed
in 75 mL of rich seed media consisting of peptone (5 g/L),
dextrose (10 g/L), yeast extract (3 g/L), and malt extract (10 g/L)
adjusted to pH 6.2 and cultured at 25uC with shaking for 6 days.
450 mL of malt extract (0.66% wt/vol) and 10 g HP-20 resin were
then added to each flask, and the fungi were cultured under the
same conditions for 21 days. The fungal culture was subsequently
incubated statically at 25uC for 5 days and filtered. The HP-20
resin with mycelia was extracted three times with 200 mL of
ethanol to yield the crude extract.
Natural product library
The natural product library, which was prepared in Costa Rica
(collection permits 307-2003-OFAU, R-CM-03-2006, R-CM-
INBio-06-2006, R-CM-INBio-082-2009, R-CM-INBio-04-2009,
R-CM-INBio-088-2009 and R-CM-INBio-094-2010), consisted
mainly of pre-fractionated extracts from microbial sources, such
as fungal endophytes and marine bacteria, although extracts
from other sources such as marine invertebrates, cyanobacteria
and lichens were also included [11]. Extracts were suspended in
dimethyl sulfoxide (DMSO) at a concentration of ,15 mg/mL.
The compound library was stored at 220uC in dessicated storage
containers.
HTS for antimicrobial activity
The first step of compound identification was an HTS for
inhibitors of V. cholerae sucrose fermentation in pH-MM
Suc
medium. A work-flow chart for this HTS is shown in Figure 1.
Fermentation decreases the pH of the medium. pH indicators in
the medium allowed us to monitor medium acidification spec-
trophotometrically through a change in absorbance at 615 nm
(A615). To initiate the assay, V. cholerae derived from a glycerol
stock was streaked on an LB-agar plate and incubated overnight at
37uC. A loopful of cells was harvested, washed three times with
PBS, and then resuspended in PBS at an optical density of 0.015.
For the HTS, 10 mL of this bacterial cell suspension was aliquoted
into the wells of a 384-well plate containing 30 mL of pH-MM
Suc
and 100 nL of the test compound. For each assay, the A615
was measured after incubation at room temperature for 6 and
20 hours. This step was automated and validated in 384-well plate
format using an EnVision
TM multi-well spectrophotometer.
Compound isolation and identification
The crude extract was resuspended in 90% water/methanol
and passed over a C18 SPE column to get fraction I. The column
was then washed with methanol to get fraction II. The compound
mixture in fraction II was separated on an Agilent 1100 series
HPLC with a preparative Phenyl-hexyl column (Phenomenex,
Luna, 25 cm610 mm, 5 mm particle size) using an elution buffer
containing 20% acetonitrile/water with 0.1% formic acid at a flow
rate of 2 mL/min for 50 minutes. This yielded compound 1 (tR:
23.5 min), compound 2 (tR: 25 min), and compound 3 (tR: 44 min).
Spectra for compound identification were obtained on an Alpha
FT-IR mass spectrometer (Bruker), an Ultrospec
TM 5300 pro UV/
Visible Spectrophotometer (Amersham Biosciences), and an
INOVA 600 MHz nuclear magnetic resonance spectrometer
(Varian).
Determination of minimum inhibitory concentrations
(MIC)
The MICs for all species except for M. tuberculosis were
determined in cation-adjusted Mueller-Hinton broth (CAMHB)
using the microdilution broth method, according to M07-A8
and M100-S21 guidelines [12,13]. Standardized inocula of each
bacterium were prepared from cultures grown overnight at 37uC
in CAMHB, which were subsequently diluted 1:50 in fresh
CAMHB and grown for 3 h at 37uC without shaking. Each log-
phase culture was diluted to deliver a final bacterial density of
5610
5 CFU per mL. To perform the tests, a dilution series of
the indicated antimicrobial agent in CAMHB was prepared from
a stock solution containing 10 mg/mL of the compound in
DMSO. The final concentrations of the natural product were
between 0.625 and 80 mg/mL. These were chosen because we
knew that the compound was active against V. cholerae within this
range. Dilutions of known antimicrobial compounds were similarly
chosen based on the reported MIC’s for the bacterium in question.
An MIC 2000 inoculator (DynaTech) was used to accurately
dispense 1.5 mL of bacterial culture into 100 mL of CAMHB alone
or supplemented with an antimicrobial agent in a 96 well plate.
The plates were prepared in duplicate and incubated overnight at
37uC. A positive control for growth containing no antimicrobial
compound but the relevant amount of DMSO and a negative
growth control containing no bacteria were also prepared for each
assay. The MIC was determined visually as the lowest antimicro-
bial agent concentration that prevented bacterial growth. The M.
tuberculosis MIC was determined by the fluorometric microplate-
Figure 1. Flow chart of HTS assay. The HTS assay begins with
manual preparation of working solutions of pH-MM
Suc and a bacterial
suspension with OD600 of 0.015 in PBS. Subsequent steps of the assay
are fully automated: solution mixing in the 384 well-plates is performed
by a ThermoScientific Matrix WellMate liquid dispenser, pin-transfer of
the natural extracts tested is done with a custom-built Epson robot, and
A615 readout after incubation at room temperature is accomplished
at 6 and 20 hours using an EnVision
TM multi-well spectrophotometer.
Finally, EnVision
TM data were analyzed with Spotfire
TM and Excel. Each
assay is performed in duplicate. A measurement was considered to be
statistically significant if it deviated by at least three standard deviations
from the mean measurement calculated using all measurements made
with a particular extract library. The calculated Z9 factor for the screen
was 0.80860.088.
doi:10.1371/journal.pone.0031307.g001
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casein (0.1% wt/vol) and lacking Tween 80 (7H9-Casein-ADC)
[14,15].
Microdilution Alamar blue assay for M. tuberculosis
Briefly, 1 mL of M. tuberculosis cell stock was added to 49 mL of
7H9-TW80-ADC media and incubated for 4–5 days at 37uC with
shaking (120 rpm) until an OD600 of 0.6–0.8 (#3–4 McFarland
turbidity standard) was reached. The cells were then washed twice
with PBS and resuspended in 7H9-Casein-ADC to a final con-
centration of 2610
5 cells/mL. 100 ml of the cell suspension was
inoculated into the wells of clear-bottomed, 96-well microplates
preloaded with 100 ml of 7H9-Casein-ADC media containing
appropriate dilutions of the test compound. Initial compound
dilutions were prepared in DMSO, and subsequent two-fold
dilutions were directly performed in the microtiter plates used for
the assay. To determine if bacterial densities were adequate for the
assay, 32.5 ml of Alamar blue solution (106Alamar blue dye, 20%
Tween 80, 86PBS, pH 7) were added to a control well after 6–7
days of growth at 37uC. If the control well remained blue or turned
purple and/or had a fluorescence reading ,17,500 fluorescence
units (FU) after 18–24 hours of further growth at 37uC, additional
control wells were tested daily until the well turned pink and the
fluorescence reading was greater than 17,500 FU’s. At this point,
the Alamar blue solution was added to the entire plate, and
the fluorescence was measured after overnight incubation. All
fluorescence measurements were performed in an HTS7000 Plus
Bio Assay Reader (Perkin Elmer) in bottom-reading mode with
excitation at 550 nm and emission at 595 nm. Percent inhibition
was defined as (experimental well FU – media only FU)/(bacteria
only FU – media only FU)6100. The lowest drug concentration
effecting $90% inhibition was considered the MIC.
Fungal identification by internal transcribed spacer
amplification (ITS) and sequencing
For fungal identification, isolate 1223-D was cultured on agar as
described above for 26 days. The mycelium was then retrieved and
ground to a fine powder in liquid nitrogen. Genomic DNA was
extracted using the Wizard Genomic DNA Purification Kit
(Promega), and the large subunit ribosomal DNA was amplified
by PCR using primers LR5 (59-TCCTGAGGGAAACTTCG-39)
and LROR (59-ACCCGCTGAACTTAAGC-39) as well as their
reverse complements. The PCR products were submitted for
sequence analysis (Genewiz), and the resulting sequences were
used in a BLAST search against deposited sequences. These se-
quences are shown in Text S1.
Results
Development of a high throughput screen
In the clinical microbiology laboratory, one of the character-
istics used to distinguish V. cholerae from other Vibrio species is its
ability to ferment sucrose on thiosulfate-citrate-bile salts-sucrose
(TCBS) plates, which contain the pH indicators bromothymol blue
and thymol blue. As the pH of a solution decreases below 7.1 for
bromothymol blue and 8.0 for thymol blue, these aromatic
compounds, which are weak acids, gain a proton resulting in a
color change from blue to yellow. This process is reversible.
Therefore, if the pH is increased again, the color of these weak
acids will return to blue. Such pH indicators are often used as
reporters of bacterial fermentation [16–18].
We recently showed that transport of sucrose by V. cholerae
depends entirely on a phosphotransfer cascade known as the pho-
sphoenolpyruvate phosphotransferase system or PTS, which also
regulates biofilm formation [10,19]. We were interested in
developing a reporter medium that would allow us to identify com-
pounds that inhibit transport through the PTS, sugar fermenta-
tion, or bacterial growth. Therefore, we added bromothymol blue
and thymol blue, the pH indicators found in TCBS agar, to
minimal medium containing sucrose (pH-MM
Suc). Based on the
pKa values of bromothymol blue and thymol blue, we predicted
that the medium would be yellow at pH,7.1, when both in-
dicators are protonated. We predicted that the medium would be
green at a pH between 7.1 and 8.0 because bromothymol blue
would be blue due to deprotonation, while thymol blue would
remain yellow. At pH.8.0, when both indicators are deproto-
nated, we anticipated that the medium would be blue.
Incubationofwild-typeV.choleraeinthismediumcauseda change
in color from green to yellow due to fermentation (Figure 2). When
the PTS mutant,which cannot utilizesucrose,wasincubated in pH-
MM
Suc, the medium turned blue, indicating an increase in the pH.
This is the result of amino acid catabolism (Figure 2), which ge-
nerates ammonia, a weak base. We hypothesized that these visible
differences in the color of the medium at low and high pH were the
resultofa changeinabsorbanceata wavelength inthevisiblerange.
To identify this wavelength, we scanned the visible spectra of pH-
MM
Suc alone, pH-MM
Suc incubated with wild-type bacteria, and
pH-MM
SucincubatedwithaPTSmutant.AsshowninFigure2,the
maximum difference in absorbance for all these conditions was
observed at a wavelength of 615 nm. We based our screen on this
observation. It consisted of a room temperature incubation of V.
choleraeinMM
Sucsupplemented withbromothymolblueandthymol
blue, and measurements of A615 at 6 and 20 hrs (Figure 1).
To validate the screen, a pilot assay was conducted in 384 well
microtiter dishes using plates 1568 and 1569 from the Prestwick
Collection, a commercial library. Wild-type V.cholerae with noadded
compound was used as a positive control, while a PTS mutant,
which is unable to transport sucrose, was used as a negative control.
One column of each dish was reserved for replicate positive controls
and another for replicate negative controls. To evaluate the
performance of our assay, we calculated a Z9 factor for each mi-
crotiter dish. This factor reflects the difference between positive and
negative control measurements [20] and is used to determine
whether the size of a response (e.g. change in absorbance) is large
enough to be useful in a HTS. A Z9 factor between 1 and 0.9 is
considered excellent, while one between 0.9 and 0.7 is considered
good. For these tests, the Z9 factor ranged from 0.785 to 0.914,
suggesting that this was a good to excellent assay. Therefore, we
proceeded with the HTS.
HTS of natural products
We carried out a screen of a library of partially purified extracts
from diverse Costa Rican organisms. The library consisted of
39,314 extracts arrayed in 384-well plates at a concentration
of ,15 mg/mL in DMSO (see: http://iccb.med.harvard.edu/
screening/compound_libraries/index.htm#natural). Each library
plate contained extracts in columns 1–22 and DMSO only
in columns 23 and 24. Compounds were pin-transferred into a
384-well plate pre-filled with pH-MM
Suc. Columns 1–23 were
then inoculated with wild-type V. cholerae, and column 24 was
inoculated with a PTS mutant. Columns 23 and 24 served as
fermentation-positive and fermentation-negative controls, respec-
tively. Each plate of extracts was tested in duplicate. A mea-
surement was considered to be both statistically and biologically
significant if it deviated by at least three standard deviations from
the mean measurement, which was calculated from measurements
derived from all the compounds screened. Statistical analysis
performed after completion of the screen yielded a Z factor with a
High Throughput Screen for Antimicrobials
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identified 126 unique extracts with possible activity against V.
cholerae.
Secondary screens
Compounds that increase the pH of the medium or that absorb
in the visible spectrum could be a source of false positives in this
assay. These were easily eliminated by detailed monitoring of
the change in A615 over time. In addition, the following secondary
screens were designed to identify (i) inhibitors of PTS sugar
transport, (ii) inhibitors of sugar fermentation, or (iii) inhibitors of
bacterial growth. To distinguish between extracts that inhibited
PTS-dependent sugar transport and those that delayed fermenta-
tion, we compared medium acidification in MM
Glu with that
in MM
Suc in the presence of crude extracts with the following
rationale. After hydrolysis, the fermentation pathway of sucrose is
similar to that of glucose. However, unlike sucrose, glucose is
transported by both PTS-dependent and PTS-independent means
[10]. Therefore, we predicted that, in the presence of specific
inhibitors of the PTS, medium acidification would proceed more
slowly in MM
Suc than in MM
Glu. In contrast, inhibitors of fer-
mentation should behave similarly in both media. Because
pyruvate is transported independently of the PTS and is not
fermented, we used growth in MM
Pyr to identify extracts that
inhibited bacterial replication. Each assay was performed in du-
plicate, and each reported value represents the average of two
experimental replicates. To account for the variability of initial
absorbance measurements, experimental data were normalized to
the initial A615 for each well.
We first compared the performance of wild-type V. cholerae and a
PTS mutant in our proposed secondary screens (Figure 3A and B).
In MM
Suc and MM
Glu containing wild-type V. cholerae alone
(Figure 3A), the A615 initially decreased but then began to rise after
approximately 5 hours of incubation. We hypothesized that the
initial decrease in A615 represented acidification of the medium
due to sugar fermentation, while the subsequent increase in A615
reflected depletion of the sugar supply and initiation of amino acid
catabolism as well as cell growth.
An increase in A615 was observed during incubation of the PTS
mutant in MM
Suc due to its inability to transport and consequently
ferment sucrose (Figure 3B). Unlike sucrose, glucose can be
transported by the PTS mutant. Therefore, in MM
Glu, the A615 of
the medium initially decreased, albeit more slowly than was
observed for incubation with wild-type V. cholerae. Lastly, wild-type
V. cholerae and the PTS mutant grew equally well in MM
Pyr.
Our secondary screen yielded 49 extracts with reproducible
effects on medium acidification by V. cholerae (see Table S1 and
Figure S1). These included (i) one extract, CR1223-D, which
delayed medium acidification by sucrose fermentation more than
that by glucose fermentation, (ii) 34 extracts that blocked growth in
pyruvate but not medium acidification, and (iii) fourteen extracts
that blocked growth in pyruvate as well as medium acidification
(representative traces are shown in Figure 3C–E). We hypothe-
sized that CR1223-D might contain an inhibitor of PTS transport.
Furthermore, we reasoned that medium acidification in the
absence of cell growth, as was seen in group (ii), reflected the
presence of viable bacteria whose growth was inhibited. Therefore,
we hypothesized that these extracts were bacteriostatic. The
absence of both medium acidification and cell growth, as was
observed in group (iii), suggested the absence of viable bacteria.
We hypothesized that these extracts were bactericidal, although it
is formally possible that these extracts contained compounds that
inhibited both sugar transport and cell growth while preserving the
viability of bacterial cells.
Because of our interest in sugar metabolism, we subsequently
focused on characterization of CR1223-D. This extract was
derived from isolate 1223-D, an unclassified endophytic fungus
harvested from the twig of Neomirandea angularis, a host plant from
the Asteraceae family. Amplification, sequencing (see SI), and
alignment of the ITS region using Mega [21] suggested that this
fungus was most closely related to the environmental fungi,
Septofusidium herbarum and Acremonium alternatum.
Figure 2. Spectrophotometric assay for bacterial sugar fermentation. Absorbance spectrum of MM
Suc alone (indicator) or incubated with
wild-type V. cholerae (WT) or a PTS mutant for 5 hours. The spectra are shown at the left, while the visible color difference is shown in microtiter dish
wells at the right. The largest difference in absorbance between MM
Suc incubated with wild-type V. cholerae and that incubated with a PTS mutant is
measured at 615 nm (red arrow).
doi:10.1371/journal.pone.0031307.g002
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products from isolate 1223-D
Extracts of fungal isolate1223-D were prepared and fractionat-
ed as described in the Materials and Methods. High resolution
mass spectrometry, infrared and ultraviolet spectrometry, and
1H
and
13C nuclear magnetic resonance spectroscopy were used to
identify compound 1 as 6-propyl gentisyl alcohol or 2-(hydro-
xymethyl)-3-propyl hydroquinone, compound 2 as 5-hydroxy-4-
(hydroxymethyl)-2-methyl 2,3-dihydrobenzofuran, and compound
3 as 2-(hydroxymethyl)-3-propyl benzoquinone (Figure 4). The
physical properties and NMR spectra of these compounds are
described in detail in Text S2 and Table S2. These are all
previously unreported natural products.
Activity of compounds 1, 2, and 3 against V. cholerae
To determine which of these compound(s) was responsible for
the activity of CR1223-D, we performed medium acidification
and growth assays in the presence of various concentrations of
compounds 1 through 3. Conditions were tested in duplicate in
each experiment, and two experimental replicates were performed
on separate days. Reproducibility was excellent. The result of one
experiment is shown in Figure 5, while the result of the replicate
experiment is shown in Figure S2. Compounds 2 and 3 had
only modest effects on medium acidification and growth even
at the highest concentrations studied. In contrast, compound 1
inhibited medium acidification at a concentration of 134 mM and
completely blocked medium acidification at a concentration of
261 mM. However, only modest effects on growth were observed
at these concentrations. At higher concentrations, compound 1
was able to completely inhibit growth of V. cholerae. To determine
whether this represented bacteriostatic or bactericidal activity,
dilutions of the cell suspensions were plated on LB agar after
20 hours of growth in MM
Pyr supplemented with compound 1 at
a concentration of 383 mM. No CFU were documented after
24 hours of incubation at 37uC, indicating that compound 1
inhibited fermentation and possibly sugar transport at lower
concentrations and was bactericidal at higher concentrations.
Thus, we concluded that compound 1 was responsible for the
inhibitory activity of CR1223-D detected in our HTS assay. We
have named compound 1 mirandamycin, after the genus of the
host plant of the producing fungus.
In vitro antimicrobial activity of mirandamycin against
other bacterial pathogens
To evaluate the antimicrobial efficacy of mirandamycin against
a broader panel of bacterial pathogens, we measured the activity
of compound 1 against clinical strains of E. coli, P. aeruginosa, car-
bapenemase-producing K. pneumonia, methicillin-resistant S. aureus,
and M. tuberculosis. As shown in Table 1, mirandamycin was most
active against Gram-positive organisms but also had some activity
against the more sensitive Gram-negative rods. Susceptibility of
these organisms to known antibiotics is shown for comparison.
Discussion
We have developed and implemented a simple, inexpensive, and
robust HTS for antibacterial agents based on a spectrophotometric
Figure 3. Representative results for secondary screen. Bacteria
were grown in MM
Pyr, pH-MM
Suc, or pH-MM
Glu.O D 615 measurements of
cultures in MM
Pyr reflect the ability of cells to grow in the presence of
extract, while absorbance measurements in pH-MM
Suc and pH-MM
Glu
reflect the ability of cells to transport and ferment these sugars in the
presence of extract. Data are shown for wild-type V. cholerae and a PTS
mutant in the absence of extract (A,B) or for wild-type V. cholere in the
presence of extracts that we hypothesize (C) interfere with sugar
transport and fermentation, (D) inhibit bacterial growth (bacteriostatic),
or (E) kill bacteria (bactericidal).
doi:10.1371/journal.pone.0031307.g003
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bacteria. Secondary screens allowed us to easily distinguish between
bactericidal and bacteriostatic compounds as well as those that
blocked sugar fermentation but did not decrease growth or viability.
As compared with other HTS for antibacterial compounds, this
screen has several advantages. First of all, the screen uses whole cells
rather than purified targets [7]. Secondly, it is an assay for cell viability
and, therefore, is biased toward bactericidal agents [22,23]. Thirdly,
because it does not require cell growth, it is rapid. Lastly, the screen
does not require expensive fluorescent reporters of cell viability.
As a proof of principle, we identified several extracts with anti-
bacterial activity. Fractionation of one of these derived from an
endophytic fungus led to the identification of three novel natural
products. One of these natural products, a hydroquinone that we
have called mirandamycin, has antibacterial activity against a wide
range of difficult to treat pathogens including P. aeruginosa, MRSA,
and M. tuberculosis.
Quinones and their corresponding reduced forms, the hydro-
quinones, are components of eukaryotic and bacterial electron
transport chains. In V. cholerae, ubiquinone-8 is reduced by the
Na+-translocating NADH:ubiquinone oxidoreductase (NQR) at
the cytoplasmic face of the inner membrane. The corresponding
hydroquinone then diffuses across the inner membrane where it is
oxidized by one of several possible quinol oxidases, discharging
protons to the periplasmic space. The resulting quinone is recycled
to the inner membrane [24]. Therefore, quinones are reduced at
the cytoplasmic face of the inner membrane and the correspond-
ing hydroquinones are oxidized at the periplasmic face.
The bactericidal secondary metabolite identified here, miran-
damycin, is a hydroquinone, closely related to homogentisic acid.
We hypothesize that the antibacterial activity of mirandamycin is
the result of an interaction with an outward facing bacterial quinol
oxidase. One possibility is that single electron oxidation of
mirandamycin by a quinol oxidase results in formation of a
semiquinone intermediate, which can then react with molecular
oxygen to produce a toxic superoxide radical. Inhibition of
bacterial quinol oxidase by mirandamycin is another possible
antibacterial mechanism.
Quinones are known to be toxic to both mammalian and
bacterial cells [25,26]. First of all, they can undergo single electron
Figure 4. Isolation and identification of three novel natural compounds. Chromatogram obtained during fractionation of the crude extract
CR1223-D showing three peaks corresponding to the three compounds isolated. Compound 1 was further identified as 6-propyl gentisyl alcohol,
compound 2 as 5-hydroxy-4-(hydroxymethyl)-2-methyl 2,3-dihydrobenzofuran, and compound 3 as 2-(hydroxymethyl)-3-propyl benzoquinone.
doi:10.1371/journal.pone.0031307.g004
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PLoS ONE | www.plosone.org 6 February 2012 | Volume 7 | Issue 2 | e31307Figure 5. Impact of compounds 1, 2, and 3 on V. cholerae sugar fermentation and growth. The assays were carried out at 30uC in pH-
MM
Suc to monitor sugar fermentation by A615 (A, B, and C) or in MM
Pyr to monitor bacterial growth by OD615 (D, E, and F). Bacteria were exposed to
mirandamycin (A and D), compound 2 (B and E) or compound 3 (C and F) at concentrations ranging from 14 to 383 mM. Replicate assay is shown in
Figure S2.
doi:10.1371/journal.pone.0031307.g005
Table 1. Minimum inhibitory concentrations (MICs) of mirandamycin and known antibiotics against selected bacterial pathogens.
Species ATCC MIC (mg/mL)
MIR LEVO AMP IMI TMP/SMX
E. coli 25922 80 0.019 2.5 1.25 0.125
P. aeruginosa 27853 80 1.25 .80 5 .16
K. pneumoniae carbapenemase positive BAA-1705 .80 .80 .80 .80 .16
MRSA BAA-976 10 0.312 .80 1.25 0.062
V. cholerae PW357 - 40 ,0.005 2.5 1.25 .16
MIR LEVO INH PZA ETH
M. tuberculosis H37Rv
(*) 27294 25 0.25 0.25 100 2
(*)MIC was determined by Alamar Blue Assay as described in Material and Methods; Mirandamycin (MIR), levofloxacin (LEVO), ampicillin (AMP), imipenem (IMI), bactrim
(TMP/SMX), isoniazid (INH), pyrazinamide (PZA), ethambutol: ETH.
doi:10.1371/journal.pone.0031307.t001
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PLoS ONE | www.plosone.org 7 February 2012 | Volume 7 | Issue 2 | e31307reduction at the cytoplasmic face of bacterial cell membranes
to form semiquinones. Secondly, quinones can interact with
thiol-containing compounds to form adducts. Interestingly, the
oxidized quinone form of mirandamycin reported here (compound
3) demonstrated no antibacterial activity. We hypothesize
that compound 3 does not enter bacterial cells and, therefore, is
not reduced to mirandamycin under the conditions of our
experiment.
Organisms that survive successfully in close proximity to bac-
terial pathogens have been a rich source of potent antibacterial
natural products. Here we present an easily implemented, sensitive
HTS that rapidly identified a large number of antibacterial
extracts from environmental samples. Through this screen, we
identified a quinol with activity against multiple pathogens. In
this era of rising resistance to existing antibiotics, approaches such
as this will be increasingly relied on to fill our antimicrobial
pipeline.
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Figure S1 Natural extracts with reproducible effects on
medium acidification by V. cholerae. Time course mea-
surements of V. cholerae medium acidification in pH-MM
Suc and
pH-MM
Glu or growth in MM
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the presence of test extracts. Extract designation is indicated above
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